Development of a Janus Kinase (JAK) Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis

While highly efficacious in treating rheumatoid arthritis (RA), the approved JAK inhibitor, Tofacitinib (Tofa, CP-690 550), has dose-dependent toxicities that limit its clinical application. In this study, we have examined whether a prodrug design that targets arthritic joints would enhance Tofa’s t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Pharm
Autores principales: Wei, Xin, Wu, Jianbo, Zhao, Gang, Galdamez, Josselyn, Lele, Subodh M., Wang, Xiaoyan, Liu, Yanzhi, Soni, Dhruvkumar M., Purdue, P. Edward, Mikuls, Ted R., Goldring, Steven R., Wang, Dong
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6078779/
https://ncbi.nlm.nih.gov/pubmed/29966420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.8b00433
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares